Ocular Therapeutix, Inc. OCUL Cash Flow

Ocular therapeutix, inc. (OCUL)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Cash flows from operating activities:
Net loss
81,984	86,372	77,754	73,986	29,089	59,978	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	0	0	-49,886	-	-42,518	-44,446	-43,010	-39,748	-37,065	-32,835	-29,218	-28,648	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense
8,482	8,759	8,755	7,459	7,594	7,483	7,643	7,520	7,447	7,321	6,935	6,554	6,312	5,956	5,569	5,431	5,068	4,640	4,281	3,657	3,062	2,644	0	0	0
Licensing and consultant fees paid in common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,364	0	0	0
Non-cash interest expense
4,322	3,683	2,601	1,630	708	397	364	383	396	408	574	510	446	371	160	163	164	166	149	152	134	103	0	0	0
Amortization of operating lease asset
-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liability
-2,317	4,310	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization expense
2,675	2,530	2,438	2,342	2,310	2,286	2,232	2,141	1,929	1,625	1,350	1,084	937	881	828	806	786	754	718	663	627	547	0	0	0
Revaluation of preferred stock warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	380	0	0	0
Purchase of premium on marketable securities
-	-	-	-	-	-	-	-	-	3	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of premium on marketable securities
-	-	-	-	-	-	-	-	-	17	30	50	93	186	0	0	0	-	-	-	-	-	-	-	-
Purchase discount on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Amortization of premium on marketable securities, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable from related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-19	0	0	0
Accounts receivable
3,153	2,347	874	330	106	-25	-38	74	-74	-24	35	-12	17	57	54	59	-125	-136	136	104	76	79	0	0	0
Prepaid expenses and other current assets
85	518	1,142	1,072	1,124	260	80	-864	-1,409	-45	-547	541	548	-924	-1,151	-1,573	-82	53	2	736	-242	36	0	0	0
Inventory
842	737	793	631	126	95	-25	41	43	9	1	-59	-31	-21	-21	4	-31	1	30	36	71	133	0	0	0
Operating lease assets
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-873	124	239	1,517	627	-796	-234	-3,529	-389	932	293	3,225	421	-159	419	-765	274	348	84	813	356	507	0	0	0
Accrued expenses and deferred rent
988	1,714	2,142	1,580	596	1,711	-269	-492	1,935	2,558	4,471	4,290	1,660	1,389	-458	10	599	219	1,384	1,124	1,338	1,946	0	0	0
Operating lease liabilities
-858	-844	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-83	-125	-250	-146	0	0	0	-	-	-	-
Net cash used in operating activities
-77,046	-77,578	-71,759	-63,088	-56,140	-49,227	-45,962	-49,471	-48,369	-50,473	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-36,120	-	-30,733	-27,366	-23,350	-20,496	0	0	0
Cash flows from investing activities:
Purchases of property and equipment
1,762	2,238	2,116	2,170	2,233	1,889	1,974	3,537	6,979	8,252	8,368	7,201	3,446	1,919	1,712	919	1,551	1,778	1,746	1,944	1,317	1,260	0	0	0
Purchases of marketable securities
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91,684	0	0	0	-	-	-	-
Proceeds from maturities of marketable securities
-	-	-	-	-	-	-	-	-	38,200	54,200	65,884	68,184	80,684	0	0	0	-	-	-	-	-	-	-	-
Net cash used in investing activities
-1,762	-2,238	-2,116	-2,170	-2,233	-1,889	-1,974	-532	18,726	26,953	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,158	-	-74,250	-46,937	-56,143	-38,586	0	0	0
Cash flows from financing activities:
Proceeds from issuance of notes payable
-	-	-	-	-	-	-	-	-	3,700	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of 2026 convertible notes, net of issuance costs
-	37,275	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
205	78	85	125	132	397	852	920	949	685	225	162	196	199	185	138	178	207	182	155	48	35	0	0	0
Proceeds from issuance of common stock upon public offering, net
45,273	37,537	34,257	28,521	31,535	61,571	56,542	45,284	37,956	29,238	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payments of insurance costs financed by a third party
-	-	-	-	-	-	-	-	-	591	721	524	522	519	611	809	785	762	0	0	0	-	-	-	-
Repayment of notes payable
-	-	-	-	-	5,657	4,114	2,571	1,029	1,300	0	0	0	-	-	-	-	-	-	-	-	2,273	0	0	0
Net cash provided by financing activities
45,859	75,341	82,578	75,339	76,713	68,640	53,518	43,674	37,758	32,008	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net (decrease) increase in cash, cash equivalents and restricted cash
-32,949	-4,475	8,703	10,081	18,340	17,524	5,582	-6,329	8,115	8,488	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65,651	-	65,289	133,045	79,266	78,970	0	0	0
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,036	-30,516	33,689	-6,609	-39,694	58,742	-227	19,888	0	0	0
Supplemental disclosure of cash flow information:
Cash paid for interest
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	844	0	0	0
Supplemental disclosure of non-cash investing and financing activities:
Accretion of redeemable convertible preferred stock to redemption value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11	0	0	0
Additions to property and equipment included in accounts payable and accrued expenses at balance sheet dates
59	214	421	331	30	155	422	-642	-148	538	631	1,532	1,329	451	-241	347	397	293	797	216	105	169	0	0	0
Derivative liability in connection with issuance of 2026 convertible notes
-	16,434	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Public offering costs included in accounts payable and accrued expenses at balance sheet dates
-	-	-	-	-	42	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0